Monoclonal Antibody Custom Service Market Share

Global Monoclonal Antibody Custom Service Market Overview

Monoclonal Antibody Custom Service Market Size was valued at USD 0.74 billion in 2023 and is projected to grow from USD 0.78 Billion in 2024 to USD 1.17 billion by 2032. The market is witnessed a compound annual growth rate (CAGR) of 5.14 % from 2024 to 2032. Higher investments in research and development activities and the escalating prevalence of chronic diseases and infections are the factors that drive the market growth. 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

The production of monoclonal antibodies, which are identical to human antibodies but were created in a laboratory, is one way to improve the functioning of the immune system. Monoclonal antibodies work by boosting the patient's immune system and preventing disease by blocking certain cell receptors. These antibodies come from a single patient. These are utilized quite frequently in pre-clinical research, both in vitro and in vivo. Many different biotechnology companies are currently providing research institutes and pharmaceutical corporations with individualized monoclonal antibody production services.

Significant advancements are being made in healthcare infrastructure all around the world, but especially in nations with low to middle incomes. This expansion is being fueled by increased funding and investments in healthcare infrastructure, as well as research and development of novel medications and therapies.

It is anticipated that these funding initiatives for healthcare research will drive the market for monoclonal antibody bespoke services. This is due to the fact that monoclonal antibodies show significant potential in treating a variety of different dangerous diseases. This element is the primary driver of the CAGR of the market.

In addition, customized medicine is the trend in the healthcare business that is expanding at the quickest rate, and it is transforming the detection, classification, and treatment of diseases. This strategy is particularly prevalent in the field of cancer, which places a significant emphasis on the use of customized monoclonal antibodies in both research and treatment. In addition, developing nations are currently making large investments in the research and development of antibody drugs, which is propelling the global market.

In the next years, it is projected that the demand for bespoke antibodies will be fueled in part by the rising prevalence of infectious diseases and chronic conditions, as well as by continuous research and development initiatives aimed at the creation of novel therapy and diagnostic alternatives. During the period covered by the prediction, developments in research infrastructure and the competitive cost advantages offered by manufacturing in developing nations are projected to encourage existing market participants to make investments in the world. As a result, boosting revenue growth for the monoclonal antibody bespoke service market.

June 2023: AMSBIO announced progress in its brand new rabbit and mouse recombinant monoclonal antibody development service that is founded on a ground-breaking technological platform. The classic hybridoma fusion methods cannot directly separate IgG genes from B cells of immunized animals, but the DimAbTM development platform can. This is one of the ways in which it stands apart from those technologies. Several projects for bespoke software development have already been finished with a high level of satisfaction among the clients thanks to the utilization of this cutting-edge platform. The new DimAb technology platform developed by AMSBIO represents a significant advancement in this sector's technological landscape. AMSBIO is capable of directly isolating IgG genes from positive B cell clones. This does not require the use of myeloma cells. Not only does this make development times more manageable, but it also makes it possible to directly get the genetic coding information for IgG.

Monoclonal Antibody Custom Service Market Trends

• Increasing investment in research & development is driving the market growth.

The healthcare infrastructure is witnessing significant development, particularly in low-middle-income countries. Increased funding and investments in healthcare infrastructure and research and development of new drugs and treatments fuel this growth. In 2018, the World Health Organization (WHO) allocated approximately USD 33 billion in grants worldwide, with the majority (65%) directed towards research. Additionally, the National Institutes of Health (NIH) experienced a funding increase of USD 3.146 billion in 2022 (7.3%) compared to 2021. These funding initiatives for healthcare research are expected to drive the market for monoclonal antibody custom services, as monoclonal antibodies show great promise in treating various serious diseases. This factor drives the market CAGR.

Additionally, personalized medicine is the fastest-growing trend in the healthcare industry that is revolutionizing disease identification, classification, and treatment. This approach is particularly prominent in oncology, where custom monoclonal antibodies play a wide role in research and therapeutics. Furthermore, emerging countries are making significant investments in antibody drug discovery, driving the market in the Region. For example, the Australian government has allocated USD 3.6 billion for basic research to support science, research, and innovation, specifically aiming to develop new products for lung conditions, such as mepolizumab, a monoclonal antibody used to treat severe asthma. The increasing incidence of infectious and chronic disorders and ongoing research and development efforts to create innovative treatment and diagnostic options are anticipated to fuel the demand for custom antibodies in the coming years. Additionally, advancements in research infrastructure and the cost advantage of manufacturing in emerging countries will likely attract market players to invest in regions like the Asia Pacific during the forecast period.Thus, driving the monoclonal antibody custom service market revenue.

Monoclonal Antibody Custom Service MarketSegment Insights

Monoclonal Antibody Custom Service Type Insights

Based on type, the Monoclonal Antibody Custom Service market segmentation includes rat custom monoclonal antibodies and rabbit custom monoclonal antibodies. The rat custom monoclonal antibody segment dominated the market; rats and mice are the perfect animal models for discovering new antibodies, and rat monoclonal antibodies have various benefits over mouse antibodies. Like humans, rats can produce various antibody isotypes such as IgA, IgD, IgE, IgG, and IgM. Additionally, they can recognize a wide range of human proteins as antigens. Rats demonstrate a stronger immune response to mouse antigens than mice, leading to greater production of lymphocytes and a reduced need for antigens.

Monoclonal Antibody Custom Service Application Insights

The market is segmented based on application, including diagnostic application (biochemical analysis for conditions like pregnancy, cancer, hormonal disorders, and infectious diseases), diagnostic imaging for diseases such as cardiovascular diseases, cancer, and bacterial infections, therapeutic application (monoclonal antibodies (MAb) as therapeutic agents and targeting agents), and Protein purification. Among these, the diagnostic application segment holds the largest market share. Monoclonal antibodies play a crucial role in this segment by detecting the presence of substances and identifying antigens in fixed tissue sections through techniques like immunohistochemistry. They are also widely used in home-testing kits for pregnancy or ovulation. Moreover, specific monoclonal antibodies are employed to label cancer cells, aiding the immune system in recognizing and eliminating them more effectively.

Monoclonal Antibody Custom Service End UserInsights

Based on end-user, the Monoclonal Antibody Custom Service market segmentation includes hospitals and research. The hospital segment dominated the market;hospitals are a significant end-user of diagnostic customized antibody products. Government and private hospitals are included in the hospital sector. Hospitals use monoclonal antibodies to treat and diagnose COVID-19, cancer, and other diseases.

Figure1: Monoclonal Antibody Custom Service Market, by End User, 2023 & 2032 (USD billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Monoclonal Antibody Custom Service Regional Insights

The market analysis includes an examination of North America, Europe, Asia-Pacific, and the Rest of the World. The North American Monoclonal Antibody Custom Service market has led the market due to various factors. These factors include the Region's significant market share, well-established healthcare infrastructure, increased funding,, and research grants from public and private sources. These factors contribute to the dominance of the North American market in the Monoclonal Antibody Custom Service sector.

The market report covers several major countries, including the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure2: MONOCLONAL ANTIBODY CUSTOM SERVICE MARKET SHARE BY REGION 2022 (%) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Monoclonal Antibody Custom Service market accounts for the second-highest market share due to the Region's growing number of chronic and neurological disorders cases. Further, the German Monoclonal Antibody Custom Service market witnessed the highest market share, and the UK Monoclonal Antibody Custom Service market was the fastest-growing market in the European Region.

The Asia-Pacific Monoclonal Antibody Custom Service Marketis expected to grow fastest from 2024 to 2032. This is due toincreasing research and development expenditures by pharmaceutical and biopharmaceutical companies, rising biotechnology research, and awareness of personalized therapeutics, which are the major factors driving the market growth. Moreover, China’s Monoclonal Antibody Custom Service market held the largest market share, and the Indian Monoclonal Antibody Custom Service market was the fastest-growing market in the Asia-Pacific region.

Monoclonal Antibody Custom Service Key Market Players& Competitive Insights

Prominent industry players are making substantial investments in research and development to enhance their product portfolios, thereby driving the growth of the monoclonal antibodies market. These market participants also engage in strategic activities to expand their presence, such as launching new products, entering into contractual agreements, pursuing mergers and acquisitions, increasing investments, and fostering collaborations with other organizations. In the increasingly competitive and growing market environment, Monoclonal Antibody Custom Service industry companies must offer cost-effective solutions to expand and thrive.

TheThe Monoclonal Antibody Custom Service industry has offered some of the most significant medical advantages. Major players in the Monoclonal Antibody market, includingThermo Fisher Scientific Inc. (US), GenScript (US), Abnova Corporation (Taiwan), and ProteoGenix (France). Several companies in the industry, are making efforts to boost market demand by allocating significant investments towards research and development activities. These companies recognize innovation's importance and are actively developing new products, technologies, and solutions.

Merck Group, a renowned German multinational science and technology company based in Darmstadt, operates in 66 countries and employs approximately 60,000 individuals. The group comprises around 250 companies, with its primary entity being Merck KGaA in Germany.Merck KGaA has collaborated with Kelun-Biotech to jointly develop seven investigational preclinical antibody-drug conjugates (ADC) for cancer treatment.

Thermo Fisher Scientific Inc. is a scientific solutions provider globally, generating approximately $40 billion in annual revenue. Their mission is to empower customers to create a healthier, cleaner, and safer world. They achieve this by supporting various endeavors such as accelerating life sciences research, addressing complex analytical challenges, enhancing laboratory productivity, advancing patient health through diagnostics, and contributing to developing and producing life-changing therapies. Thermo Fisher Scientific acquired The Binding Site Group, a prominent player in specialty diagnostics with a presence.

Key CompaniesIn The Monoclonal Antibody Custom Service Market Include

• 
  

  Thermo Fisher Scientific Inc. (US)

  
  


• 
  

  GenScript (US)

  
  


• 
  

  Abnova Corporation (Taiwan)

  
  


• 
  

  ProteoGenix (France)

  
  

Monoclonal Antibody Custom Service Industry Developments

December 2022:Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for cancer treatment.

October 2022: Thermo Fisher Scientific Inc. is a leader in scientific solutions. Thermo Fisher Scientific provides a huge range of products and services that cater to various scientific needs, including advancing life sciences research, addressing complex analytical challenges, enhancing laboratory productivity, improving patient healthcare through diagnostics, and developing transformative therapies. In line with its growth strategy, Thermo Fisher Scientific has successfully acquired The Binding Site Group, a renowned company specializing in specialty diagnostics on a scale.

Monoclonal Antibody Custom Service Market Segmentation

Monoclonal Antibody Custom Service Type Outlook

• 
  

  Rat Custom Monoclonal Antibody

  
  


• 
  

  Rabbit Custom Monoclonal Antibody

  
  

Monoclonal Antibody Custom Application Outlook

• 
  

  Diagnostic Application (Biochemical Analysis (Pregnancy Cancer, Hormonal Disorder and Infectious Diseases)

  
  


• 
  

  Diagnostic Imaging (Cardiovascular Diseases, Cancer, and Bacterial Infections)

  
  


• 
  

  Therapeutic Application (MAb as Therapeutic Agents and MAb as Targeting Agents)

  
  


• 
  

  Protein Purification

  
  

Monoclonal Antibody Custom End User Outlook

• 
  

  Hospitals

  
  


• 
  

  Research

  
  

Monoclonal Antibody Custom Service Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America